Weifa is a leading provider of APIs (Active Pharmaceutical Ingredients) to the global pharmaceutical industry. The offering is centered on two key products: Metformin for use in diabetes II medication and Opioids for use in pain treatment.
Since 1969, Weifa has built significant capacity and expertise as an API provider. Production takes place at the company’s two facilities in Kragerø, Norway, both certified according to Good Manufacturing Practice (GMP) and successfully inspected by the US Food and Drug Administration (FDA) in 2011. The products are marketed in more than 50 countries around the world.
Metformin
Leading supplier of high-quality Metformin
Weifa commands around 8 percent of the global market for metformin, an active ingredient in first-line treatment of diabetes II.
We serve more than 30 leading pharmaceutical companies. Our present strongholds are Japanese and European customers with high quality requirements, and with export to USA.
Weifa produces Metformin at a dedicated modern plant in Kragerø, Norway – the world’s largest production line for Metformin. In a strictly controlled process, Metformin is synthesised and processed to provide among the purest and best free-flowing qualities in the market. To meet different customer requirements, the plant produces Metformin in different forms:
- Metformin HCl
- Direct compressible granulate (DC)
- Tablets (250 mg, 500 mg, 850 mg and 1000 mg)
Current capacity is 3000 MT/year, but the plant is prepared for upgrade to 6000 MT.
See here for Metformin HCl spesifications.
Opioids
Leading European supplier of Opioids
Weifa serves the world market for Opioid APIs with two key products.
- Codeine Phosphate Hemihydrate – used in analgesics and cough syrup.
- Pholcodine – used in cough syrup.
The customer list counts more than 20 leading pharmaceutical companies worldwide. Weifa currently ranks among the top European suppliers of Codeine Phosphate Hemihydrate, with a global market share of 6-7 percent. For Pholcodine, the global market share is 15-20 percent.
Our strong position is built on proven high-quality products and our ability to handle controlled drugs efficiently. We offer a swift license process with the Norwegian Medicines Agency, enabling rapid execution of new orders.
The table below details the quality approval status of our opioid API production process.
| Product | Certificates | Pharmacopoeia |
|---|---|---|
| Codeine Phosphate Hemihydrate | CEP, DMF | BP, Ph. Eur |
| Pholcodine | Ph. Eur |
See here for product specifications
